Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Structure/Function Claims For Monograph Conditions Format Flexible - FDA

This article was originally published in The Tan Sheet

Executive Summary

Dietary supplements making structure/function statements based on OTC monograph claims are not required to use the "Drug Facts" format to present material information covered under a monograph, FDA Associate Chief Counsel for Foods Louisa Nickerson said Feb. 16.

You may also be interested in...



Supplement Firms' Cooperation With Trade Groups, Testing Labs Urged

Dietary supplement manufacturers should look upon industry trade associations as a vehicle for broad-based marketing of supplement ingredients' health benefits, a Nutrilite exec suggested at a Center for Business Intelligence seminar in Washington, D.C. April 18.

Supplement Firms' Cooperation With Trade Groups, Testing Labs Urged

Dietary supplement manufacturers should look upon industry trade associations as a vehicle for broad-based marketing of supplement ingredients' health benefits, a Nutrilite exec suggested at a Center for Business Intelligence seminar in Washington, D.C. April 18.

Supplement Firms' Cooperation With Trade Groups, Testing Labs Urged

Dietary supplement manufacturers should look upon industry trade associations as a vehicle for broad-based marketing of supplement ingredients' health benefits, a Nutrilite exec suggested at a Center for Business Intelligence seminar in Washington, D.C. April 18.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel